Sodium Thiosulfate Injection for Calcium Deposits in Connective Tissue Diseases
Tests sodium thiosulfate injected into calcium deposits in adults with scleroderma or related diseases.
Plain-language title generated from the registry record
Registry title: Intralesional Injection of STS in Treatment of Calcinosis
Key facts
- Where
- Pittsburgh, United StatesSee the site
- Phase
- Phase 2
Where in United States
- UPMC Arthritis and Autoimmunity CenterPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Robyn T. Domsic, MD, MPH
- Trial code
- NCT06672822
- Record updated
- 5 May 2026
- Original description
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.Read full original descriptionShow less
An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
Inclusion: Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy; Must be over 18 years of age; Participants must be competent to give informed consent; Participants must have radiographic evidence (xray or ultrasound) of calcinosis; Participants must need symptomatic relief.
Exclusion: Pregnant women will be excluded.